Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 1Phase 1/2 1

Status

Recruiting 12Completed 12Active not recruiting 12Unknown 1Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Recurrence 1Breast Neoplasms 1

Interventions

Capecitabine 25Oxaliplatin 24Paclitaxel 23Gemcitabine 21Cisplatin 21Fluorouracil 20Carboplatin 18Drug Therapy 17Docetaxel 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Injections 10Radiation 9Pemetrexed 9Magnetic Resonance Spectroscopy 9Bevacizumab 9toripalimab 8Cetuximab 8Surgical Procedures, Operative 7Specimen Handling 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6atezolizumab 6Topotecan 6Cyclophosphamide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × eribulin × Clear all
NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
400 enrolled
Breast

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡